D.E. Shaw & Co
BHVN

D.E. Shaw & Co’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

D.E. Shaw & Co’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-101,674
Closed -$15.4M – 5608
2022
Q3 		$15.4M Sell
101,674
-127,073
-56% -$18.8M 0.02% 1030
2022
Q2 		$33.3M Buy
228,747
+221,116
+2,898% +$28.2M 0.04% 584
2022
Q1 		$905K Sell
7,631
-43,376
-85% -$5.41M ﹤0.01% 3998
2021
Q4 		$7.03M Sell
51,007
-69,703
-58% -$8.86M 0.01% 2023
2021
Q3 		$16.8M Buy
120,710
+72,656
+151% +$9.07M 0.02% 1135
2021
Q2 		$4.67M Sell
48,054
-90,281
-65% -$7.33M ﹤0.01% 2115
2021
Q1 		$9.46M Sell
138,335
-25,174
-15% -$2.04M 0.01% 1396
2020
Q4 		$14M Sell
163,509
-16,388
-9% -$1.39M 0.01% 1169
2020
Q3 		$11.7M Buy
179,897
+55,957
+45% +$3.67M 0.01% 1143
2020
Q2 		$9.06M Sell
123,940
-14,957
-11% -$796K 0.01% 1244
2020
Q1 		$4.73M Buy
138,897
+2,632
+2% +$120K 0.01% 1512
2019
Q4 		$7.42M Sell
136,265
-58,989
-30% -$2.92M 0.01% 1421
2019
Q3 		$8.15M Sell
195,254
-41,662
-18% -$1.76M 0.01% 1307
2019
Q2 		$10.4M Buy
236,916
+197,879
+507% +$11.2M 0.01% 1117
2019
Q1 		$2.01M Buy
+39,037
New +$1.69M ﹤0.01% 2155

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $403M AUM 28.73% 1-Year Est. Return

D.E. Shaw & Co's BHVN Position: Q4 2022 in Review

D.E. Shaw & Co sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 101,674 shares — an estimated $15.4M sold.

D.E. Shaw & Co first reported a position in BHVN in Q1 2019 and held it in 15 quarters. The position peaked at $33.3M in Q2 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • D.E. Shaw & Co reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 101,674 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $15.4M.
  • D.E. Shaw & Co first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2019 and held it in 15 quarters.
  • D.E. Shaw & Co's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $33.3M in Q2 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on D.E. Shaw & Co's 13F filing for Q4 2022, filed 14 Feb 2023.